Reversal of Propofol-induced Depression of the Hypoxic Ventilatory Response by BK-channel Blocker ENA-001: A Randomized Controlled Trial.

Autor:	Jansen SC; Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands., van Lemmen M; Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands., Olofsen E; Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands., Moss L; Centre for Human Drug Research, Leiden, The Netherlands., Pergolizzi JV Jr; Enalare Therapeutics Inc., Princeton, New Jersey; NEMA Research Inc., Naples, Florida., Miller T; Enalare Therapeutics Inc., Princeton, New Jersey; Department of Pediatrics, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania., Colucci RD; NEMA Research Inc., Naples, Florida; Colucci & Associates, LLC, Newtown, Connecticut., van Velzen M; Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands., Kremer P; Centre for Human Drug Research, Leiden, The Netherlands., Dahan A; Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands; PainLess Foundation, Leiden, The Netherlands., van der Schrier R; Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands., Niesters M; Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands; PainLess Foundation, Leiden, The Netherlands.
Jazyk:	angličtina
Zdroj:	Anesthesiology [Anesthesiology] 2024 Jun 01; Vol. 140 (6), pp. 1076-1087.
DOI:	10.1097/ALN.0000000000004915
Abstrakt:	Background: The use of anesthetics may result in depression of the hypoxic ventilatory response. Since there are no receptor-specific antagonists for most anesthetics, there is the need for agnostic respiratory stimulants that increase respiratory drive irrespective of its cause. The authors tested whether ENA-001, an agnostic respiratory stimulant that blocks carotid body BK-channels, could restore the hypoxic ventilatory response during propofol infusion. They hypothesize that ENA-001 is able to fully restore the hypoxic ventilatory response. Methods: In this randomized, double-blind crossover trial, 14 male and female healthy volunteers were randomized to receive placebo and low- and high-dose ENA-001 on three separate occasions. On each occasion, isohypercapnic hypoxic ventilatory responses were measured during a fixed sequence of placebo, followed by low- and high-dose propofol infusion. The authors conducted a population pharmacokinetic/pharmacodynamic analysis that included oxygen and carbon dioxide kinetics. Results: Twelve subjects completed the three sessions; no serious adverse events occurred. The propofol concentrations were 0.6 and 2.0 µg/ml at low and high dose, respectively. The ENA-001 concentrations were 0.6 and 1.0 µg/ml at low and high dose, respectively. The propofol concentration that reduced the hypoxic ventilatory response by 50% was 1.47 ± 0.20 µg/ml. The steady state ENA-001 concentration to increase the depressed ventilatory response by 50% was 0.51 ± 0.04 µg/ml. A concentration of 1 µg/ml ENA-001 was required for full reversal of the propofol effect at the propofol concentration that reduced the hypoxic ventilatory response by 50%. Conclusions: In this pilot study, the authors demonstrated that ENA-001 restored the hypoxic ventilatory response impaired by propofol. This finding is not only of clinical importance but also provides mechanistic insights into the peripheral stimulation of breathing with ENA-001 overcoming central depression by propofol. (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Anesthesiologists.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu